Erasmus School of Health Policy & Management
Endowed professor | Health Technology Assessment (HTA)
- retel@eshpm.eur.nl
More information
Work
- Fábio Cardoso Borges, Winette T.A. van der Graaf, Robbe Saesen, Stefan Aebi, Ana E. Amariutei, Justin Bekelman, Thierry Gorlia, Frank Hulstaert, Isabelle Huys, Paul Kluetz, Michael J. Morris, Vijay Patil, Sheila A. Prindiville, Richard L. Schilsky, Andrew Thomson, Shaun Treweek, Michael Weller, Mira Zuidgeest, Valesca Retel & Denis Lacombe (2025) - Defining the role of pragmatic clinical trials in cancer clinical research: outcomes of a collaborative workshop hosted by the European Organisation for Research and Treatment of Cancer - The Lancet Oncology, 26 (5), e253-e263 - doi: 10.1016/S1470-2045(24)00756-3 - [link]
- Jinjing Fu, Nora Franzen, Eline Aas, J. C. Koen van der Mijn, Pim J. van Leeuwen & Valesca P. Retel (2025) - Early Cost-Effectiveness Analysis of Using Whole-Genome Sequencing for Patients With Castration-Resistant Prostate Cancer - Value in Health, 28 (5), 720-729 - doi: 10.1016/j.jval.2025.02.004 - [link]
- Astrid Kramer, Lucas F. van Schaik, Daan van den Broek, , Gerrit A. Meijer, Iñaki Gutierrez Ibarluzea, Lorea Galnares Cordero, Remond J.A. Fijneman, Marjolijn J.L. Ligtenberg, Ed Schuuring, Wim H. van Harten, Veerle M.H. Coupé & Valesca P. Retèl (2025) - Towards Recommendations for Cost-Effectiveness Analysis of Predictive, Prognostic, and Serial Biomarker Tests in Oncology - PharmacoEconomics, 43 (5), 483-497 - doi: 10.1007/s40273-025-01470-7 - [link]
- M. D. Egeler, E. Boomstra, M. W. Rohaan, N. M.J. Van den Heuvel, I. Fraterman, M. Delfos, L. V. van de Poll-Franse, T. H. Borch, I. M. Svane, J. B.A.G. Haanen, V. P. Retèl & A. H. Boekhout (2025) - “One more chance to survive”: the experiences of patients with advanced melanoma and their partners with tumor-infiltrating lymphocyte therapy—a qualitative study and recommendations for future care - Journal of Cancer Survivorship, 19 (1), 109-120 - doi: 10.1007/s11764-023-01452-8 - [link]
- Danalyn Byng, Michael Schaapveld, Esther H. Lips, Frederieke H. van Duijnhoven, Jelle Wesseling, Wim H. van Harten & Valesca P. Retèl (2024) - An early economic evaluation of active surveillance for low-risk ductal carcinoma <i>in situ</i> - Future Oncology, 20 (40), 3451-3462 - doi: 10.1080/14796694.2024.2421152 - [link]
- Lucas Frederik van Schaik, Ellen Gurumay Engelhardt, Wim Herbert van Harten & Valesca Pavlawna Retèl (2024) - Relevant factors for policy concerning comprehensive genomic profiling in oncology: stakeholder perspectives - BMC Cancer, 24 (1) - doi: 10.1186/s12885-024-13167-9 - [link]
- Astrid Kramer, Carmen Rubio-Alarcón, Daan van den Broek, Daan C.L. Vessies, Iris van't Erve, Gerrit A. Meijer, Geraldine R. Vink, Ed Schuuring, Remond J.A. Fijneman, Veerle M.H. Coupé & Valesca P. Retèl (2024) - A scenario-drafting study to explore potential future implementation pathways of circulating tumor DNA testing in oncology - Molecular Oncology, 18 (11), 2730-2742 - doi: 10.1002/1878-0261.13562 - [link]
- L. F. van Schaik, E. G. Engelhardt, E. A. Wilthagen, N. Steeghs, A. Fernández Coves, M. A. Joore, W. H. van Harten & V. P. Retèl (2024) - Factors for a broad technology assessment of comprehensive genomic profiling in advanced cancer, a systematic review - Critical Reviews in Oncology/Hematology, 202 - doi: 10.1016/j.critrevonc.2024.104441 - [link]
- Joost G.E. Verbeek, Leyla Azarang, Luis Pilli, Vincent M.T. de Jong, Agnes Jager, Sabine C. Linn, Valesca Retel & Wim Van Harten (2024) - High-dose chemotherapy for patients with stage III breast cancer with homologous recombination deficiency: a discrete choice experiment among healthcare providers - Acta Oncologica, 63, 701-709 - doi: 10.2340/1651-226X.2024.40276
- Michail Ignatiadis, Fiorita Poulakaki, Tanja Spanic, Etienne Brain, Denis Lacombe, Gabe S. Sonke, Anne Vincent-Salomon, Frederieke Van Duijnhoven, Icro Meattini, Orit Kaidar-Person, Philippe Aftimos, Frederic Lecouvet, Fatima Cardoso, Valesca P. Retèl & David Cameron (2024) - EBCC-14 manifesto: Addressing disparities in access to innovation for patients with metastatic breast cancer across Europe - European Journal of Cancer, 207 - doi: 10.1016/j.ejca.2024.114156 - [link]
Health Economics Organisation European Cancer Inst
- Start date approval
- september 2021
- End date approval
- december 9999
- Place
- BRUSSEL
- Description
- Coordinator werkgroep
KWF
- Start date approval
- september 2021
- End date approval
- december 9999
- Place
- ROTTERDAM
- Description
- Lid beoordelingscommissie
NKI-AVL Amsterdam
- Start date approval
- september 2021
- End date approval
- december 9999
- Place
- AMSTERDAM
- Description
- Hoofd afdeling Health Technology Assessment
ZonMW
- Start date approval
- september 2021
- End date approval
- december 9999
- Place
- DEN HAAG
- Description
- Lid beoordelingscommissie
Master Thesis HEPL
- Level
- master
- Year Level
- master
- Year
- 2024
- Course Code
- GW4555M
Master Thesis HE
- Year Level
- master, master
- Year
- 2024
- Course Code
- GW4592M
Module Knowledge
- Level
- bachelor 2
- Year Level
- bachelor 2
- Year
- 2024
- Course Code
- GW205K
Master Thesis Eu-HEM
- Level
- master
- Year Level
- master
- Year
- 2024
- Course Code
- GW4560M
